Gregory Wang, MD
Nephrology · Fairfax, VANPI 1871778068
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,124 of the $3,039 with a category attached, or 69.9%. 24 manufacturers reported payments, led by Novartis at 40.5% of the total. Reporting peaked in 2023 at $1,618 and has fallen 66.9% since, to $536 in 2025.
Across 94 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$248
- Vifor Pharma, Inc.$179
- Akebia Therapeutics Inc$175
- OPKO Pharmaceuticals, LLC$132
- Otsuka America Pharmaceutical, Inc.$130
- plus $944 from 18 others
Across 7 payments — averaging $3879.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$27K
Across 2 payments — averaging $131.54 each. An ownership or investment interest held by the physician or an immediate family member.
- Exthera Medical Corporation$263
What the payments were for
- Travel & lodging$70423%
- Food & beverage$2,12470%
- Education$2117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $1,232 |
| Amgen(2 entities) | 10 | $248 |
| Vifor Pharma, Inc. | 9 | $179 |
| Akebia Therapeutics Inc | 4 | $175 |
| OPKO Pharmaceuticals, LLC | 4 | $132 |
| Otsuka America Pharmaceutical, Inc. | 4 | $130 |
| Mallinckrodt Hospital Products Inc. | 5 | $129 |
| Calliditas Therapeutics US Inc. | 6 | $128 |
| ANI Pharmaceuticals, Inc. | 4 | $123 |
| GSK | 4 | $97 |
| Aurinia Pharma U.S., Inc. | 3 | $79 |
| AstraZeneca(2 entities) | 3 | $60 |
| Ardelyx, Inc. | 2 | $58 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Cook Medical LLC | 2 | $34 |
| Travere Therapeutics, Inc. | 1 | $29 |
| Sanofi | 1 | $28 |
| Argon Medical Devices, Inc. | 1 | $28 |
| Cormedix Inc. | 1 | $26 |
| Recor Medical Inc | 1 | $22 |
| Bayer | 1 | $19 |
| Covidien LP | 1 | $19 |
| Philips North America LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$3,039 in reported general payments places this provider in the 75th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 29 | $22,657 |
| Cinacalcet Hcl | 14 | $19,952 |
| RayaldeeCalcifediol | 12 | $14,365 |
| KerendiaFinerenone | 11 | $13,216 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $8,591 |
| JardianceEmpagliflozin | 11 | $6,448 |
| Sevelamer Carbonate | 37 | $6,076 |
| Hydroxychloroquine Sulfate | 12 | $1,795 |
| Losartan Potassium | 156 | $1,668 |
| Mycophenolate Mofetil | 13 | $1,471 |
| Calcitriol | 78 | $1,182 |
| Amlodipine Besylate | 116 | $1,078 |
| Calcium Acetate | 17 | $1,064 |
| Furosemide | 138 | $1,038 |
| Rosuvastatin Calcium | 25 | $874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $60 | $22,65729 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $132 | $14,36512 claims |
| BayerKerendia | $19 | $13,21611 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $123 | $26213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 298 nephrology providers in Virginia.
Other nephrology in Fairfax
- Reza ZonoziFairfax$262K
- Renuka SothinathanFairfax$68K
- Ali AssefiFairfax$64K
- Kinjal PatelFairfax$31K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Renu Regunathan-ShenkFairfax$6K
- Ranjit CheriyanFairfax$4K
- Ramon MendezWoodbridge$791K
- Sandeep MagoonNorfolk$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.